Sebela Ireland Ltd Drug Patent Portfolio
Sebela Ireland Ltd owns 5 orange book drugs protected by 17 US patents with Lotronex having the least patent protection, holding only 2 patents. And Naftin with maximum patent protection, holding 6 patents. Given below is the list of Sebela Ireland Ltd's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166205 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10166206 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10695303 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US10729667 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US8778365 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US9161914 | Topical compositions and methods for making and using same | 31 Jan, 2033 | Active |
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine | 06 Apr, 2029 | Active |
| US8486456 | Itraconazole compositions with improved bioavailability | 03 Oct, 2028 | Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine | 04 Aug, 2026 | Active |
| US7598271 | Crystalline paroxetine methane sulfonate | 04 May, 2025 | Active |
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome | 05 Oct, 2018 | Expired |
| US5874447 | 4-Phenylpiperidine compounds for treating depression | 10 Jun, 2017 | Expired |
| US6509038 | Antifungal compositions with improved bioavailability | 12 May, 2017 | Expired |
| US7081255 | Antifungal compositions with improved bioavailability | 12 May, 2017 | Expired |
| US8591948 | Antifungal compositions with improved bioavailability | 12 May, 2017 | Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives | 13 Jan, 2013 | Expired |
Latest Legal Activities on Sebela Ireland Ltd's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Sebela Ireland Ltd.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Yr, Small Entity | 17 Jan, 2024 | US10729667 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 03 Jan, 2024 | US9393237 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 13 Dec, 2023 | US10695303 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 05 Apr, 2023 | US9161914 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 20 Jul, 2022 | US8946251 (Litigated) |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166205 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 Jun, 2022 | US10166206 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 29 Dec, 2021 | US8778365 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 11 Aug, 2021 | US8658663 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 06 Jul, 2021 | US10729667 |
|
Email Notification
Critical
| 06 Jul, 2021 | US10729667 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US10166205 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US8658663 (Litigated) |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US10166206 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 02 Jul, 2021 | US9393237 |
Sebela Ireland Ltd's Drug Patent Litigations
Sebela Ireland Ltd's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 30, 2012, against patent number US8658663. The petitioner , challenged the validity of this patent, with Patricia Allison Tewes Richards as the respondent. Click below to track the latest information on how companies are challenging Sebela Ireland Ltd's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8658663 | January, 2012 |
Decision
(21 Oct, 2013)
| Patricia Allison Tewes Richards | |
Sebela Ireland Ltd's Family Patents
Sebela Ireland Ltd Drug List
Given below is the complete list of Sebela Ireland Ltd's drugs and the patents protecting them.
1. Brisdelle
Brisdelle is protected by 5 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8658663 | Method of treating thermoregulatory disfunction with paroxetine |
06 Apr, 2029
(4 years from now)
| Active |
| US8946251 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(1 year, 8 months from now)
| Active |
| US9393237 | Method of treating thermoregulatory dysfunction with paroxetine |
04 Aug, 2026
(1 year, 8 months from now)
| Active |
| US7598271 | Crystalline paroxetine methane sulfonate |
04 May, 2025
(5 months from now)
| Active |
| US5874447 | 4-Phenylpiperidine compounds for treating depression |
10 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Brisdelle's drug page
2. Lotronex
Lotronex is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6284770 | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
05 Oct, 2018
(6 years ago)
| Expired |
| US5360800 | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
13 Jan, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lotronex's drug page
3. Naftin
Naftin is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10166205 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
| US10166206 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
| US10695303 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
| US10729667 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
| US8778365 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
| US9161914 | Topical compositions and methods for making and using same |
31 Jan, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Naftin's drug page
4. Onmel
Onmel is protected by 4 patents, out of which 3 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8486456 | Itraconazole compositions with improved bioavailability |
03 Oct, 2028
(3 years from now)
| Active |
| US6509038 | Antifungal compositions with improved bioavailability |
12 May, 2017
(7 years ago)
| Expired |
| US7081255 | Antifungal compositions with improved bioavailability |
12 May, 2017
(7 years ago)
| Expired |
| US8591948 | Antifungal compositions with improved bioavailability |
12 May, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Onmel's drug page
5. Pexeva
Pexeva is protected by 2 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7598271 | Crystalline paroxetine methane sulfonate |
04 May, 2025
(5 months from now)
| Active |
| US5874447 | 4-Phenylpiperidine compounds for treating depression |
10 Jun, 2017
(7 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pexeva's drug page